190 related articles for article (PubMed ID: 30733479)
1. Novel insights into P450 BM3 interactions with FDA-approved antifungal azole drugs.
Jeffreys LN; Poddar H; Golovanova M; Levy CW; Girvan HM; McLean KJ; Voice MW; Leys D; Munro AW
Sci Rep; 2019 Feb; 9(1):1577. PubMed ID: 30733479
[TBL] [Abstract][Full Text] [Related]
2. Antifungal Azoles: Structural Insights into Undesired Tight Binding to Cholesterol-Metabolizing CYP46A1.
Mast N; Zheng W; Stout CD; Pikuleva IA
Mol Pharmacol; 2013 Jul; 84(1):86-94. PubMed ID: 23604141
[TBL] [Abstract][Full Text] [Related]
3. Novel haem co-ordination variants of flavocytochrome P450BM3.
Girvan HM; Toogood HS; Littleford RE; Seward HE; Smith WE; Ekanem IS; Leys D; Cheesman MR; Munro AW
Biochem J; 2009 Jan; 417(1):65-76. PubMed ID: 18721129
[TBL] [Abstract][Full Text] [Related]
4. Imidazolyl carboxylic acids as mechanistic probes of flavocytochrome P-450 BM3.
Noble MA; Quaroni L; Chumanov GD; Turner KL; Chapman SK; Hanzlik RP; Munro AW
Biochemistry; 1998 Nov; 37(45):15799-807. PubMed ID: 9843385
[TBL] [Abstract][Full Text] [Related]
5. Structural and spectroscopic characterization of P450 BM3 mutants with unprecedented P450 heme iron ligand sets. New heme ligation states influence conformational equilibria in P450 BM3.
Girvan HM; Seward HE; Toogood HS; Cheesman MR; Leys D; Munro AW
J Biol Chem; 2007 Jan; 282(1):564-72. PubMed ID: 17077084
[TBL] [Abstract][Full Text] [Related]
6. Crystallographic insights into a cobalt (III) sepulchrate based alternative cofactor system of P450 BM3 monooxygenase.
Panneerselvam S; Shehzad A; Mueller-Dieckmann J; Wilmanns M; Bocola M; Davari MD; Schwaneberg U
Biochim Biophys Acta Proteins Proteom; 2018 Jan; 1866(1):134-140. PubMed ID: 28739446
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the structure and interactions of P450 BM3 using hybrid mass spectrometry approaches.
Jeffreys LN; Pacholarz KJ; Johannissen LO; Girvan HM; Barran PE; Voice MW; Munro AW
J Biol Chem; 2020 May; 295(22):7595-7607. PubMed ID: 32303637
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of the Mycobacterium tuberculosis P450 CYP121-fluconazole complex reveals new azole drug-P450 binding mode.
Seward HE; Roujeinikova A; McLean KJ; Munro AW; Leys D
J Biol Chem; 2006 Dec; 281(51):39437-43. PubMed ID: 17028183
[TBL] [Abstract][Full Text] [Related]
9. Electron transfer in flavocytochrome P450 BM3: kinetics of flavin reduction and oxidation, the role of cysteine 999, and relationships with mammalian cytochrome P450 reductase.
Roitel O; Scrutton NS; Munro AW
Biochemistry; 2003 Sep; 42(36):10809-21. PubMed ID: 12962506
[TBL] [Abstract][Full Text] [Related]
10. How do azoles inhibit cytochrome P450 enzymes? A density functional study.
Balding PR; Porro CS; McLean KJ; Sutcliffe MJ; Maréchal JD; Munro AW; de Visser SP
J Phys Chem A; 2008 Dec; 112(50):12911-8. PubMed ID: 18563875
[TBL] [Abstract][Full Text] [Related]
11. Human P450-like oxidation of diverse proton pump inhibitor drugs by 'gatekeeper' mutants of flavocytochrome P450 BM3.
Butler CF; Peet C; McLean KJ; Baynham MT; Blankley RT; Fisher K; Rigby SE; Leys D; Voice MW; Munro AW
Biochem J; 2014 Jun; 460(2):247-59. PubMed ID: 24588219
[TBL] [Abstract][Full Text] [Related]
12. 4-cyanopyridine, a versatile spectroscopic probe for cytochrome P450 BM3.
Ost TW; Clark JP; Anderson JL; Yellowlees LJ; Daff S; Chapman SK
J Biol Chem; 2004 Nov; 279(47):48876-82. PubMed ID: 15364917
[TBL] [Abstract][Full Text] [Related]
13. Fluorescence detection of ligand binding to labeled cytochrome P450 BM3.
Ferrero VE; Di Nardo G; Catucci G; Sadeghi SJ; Gilardi G
Dalton Trans; 2012 Feb; 41(7):2018-25. PubMed ID: 22180859
[TBL] [Abstract][Full Text] [Related]
14. Structural analysis of Cytochrome P450 BM3 mutant M11 in complex with dithiothreitol.
Frydenvang K; Verkade-Vreeker MCA; Dohmen F; Commandeur JNM; Rafiq M; Mirza O; Jørgensen FS; Geerke DP
PLoS One; 2019; 14(5):e0217292. PubMed ID: 31125381
[TBL] [Abstract][Full Text] [Related]
15. The role of cytochrome P450 BM3 phenylalanine-87 and threonine-268 in binding organic hydroperoxides.
Roberts AG; Katayama J; Kaspera R; Ledwitch KV; Le Trong I; Stenkamp RE; Thompson JA; Totah RA
Biochim Biophys Acta; 2016 Apr; 1860(4):669-77. PubMed ID: 26723172
[TBL] [Abstract][Full Text] [Related]
16. The Aspergillus fumigatus Damage Resistance Protein Family Coordinately Regulates Ergosterol Biosynthesis and Azole Susceptibility.
Song J; Zhai P; Zhang Y; Zhang C; Sang H; Han G; Keller NP; Lu L
mBio; 2016 Feb; 7(1):e01919-15. PubMed ID: 26908577
[TBL] [Abstract][Full Text] [Related]
17. Molecular dynamics simulations of P450 BM3--examination of substrate-induced conformational change.
Chang YT; Loew GH
J Biomol Struct Dyn; 1999 Jun; 16(6):1189-203. PubMed ID: 10447203
[TBL] [Abstract][Full Text] [Related]
18. Structural and spectroscopic analysis of the F393H mutant of flavocytochrome P450 BM3.
Ost TW; Munro AW; Mowat CG; Taylor PR; Pesseguiero A; Fulco AJ; Cho AK; Cheesman MA; Walkinshaw MD; Chapman SK
Biochemistry; 2001 Nov; 40(45):13430-8. PubMed ID: 11695889
[TBL] [Abstract][Full Text] [Related]
19. Molecular modelling of lanosterol 14 alpha-demethylase (CYP51) from Saccharomyces cerevisiae via homology with CYP102, a unique bacterial cytochrome P450 isoform: quantitative structure-activity relationships (QSARs) within two related series of antifungal azole derivatives.
Lewis DF; Wiseman A; Tarbit MH
J Enzyme Inhib; 1999; 14(3):175-92. PubMed ID: 10445042
[TBL] [Abstract][Full Text] [Related]
20. Docking analysis of a series of cytochrome P-450(14) alpha DM inhibiting azole antifungals.
Talele TT; Hariprasad V; Kulkarni VM
Drug Des Discov; 1998 May; 15(3):181-90. PubMed ID: 9689500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
